Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-AI-23-019

Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Flaviviridae and Togaviridae (U19 Clinical Trial Not Allowed)

Closed on June 8, 2023.

Posted
March 16, 2023
Close date
June 8, 2023
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $46,715,173 in first-year total cost, median $46,715,173.

Most frequent study sections

  1. Special Emphasis Panel[ZAI1 SJ-M (J1)]1

Most frequent institutions

  1. WASHINGTON UNIVERSITY1
Competing awards under RFA-AI-23-019 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024Flavivirus and Alphavirus ReVAMPP (FLARE)1U19AI181960-01DIAMOND, MICHAEL SKUHN, RICHARD J.WASHINGTON UNIVERSITY, MO$46,715,173ZAI1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
RFA-AI-23-019: Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Flaviviridae and Togaviridae (U19 Clinical Trial Not Allowed) | ScienceDex | ConductScience